HuidaGene Therapeutics' HG202, a CRISPR/Cas13 RNA-editing therapy, has received FDA clearance for a Phase 1 clinical trial to treat neovascular age-related macular degeneration (nAMD).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.